Kymera IPO Presentation Deck

CANCER FIBROSIS shown pos KYMERA Autoimmune Fibrosis STAT3 Degrader In Vivo Active in Preclinical PD-1/L-1 Refractory Solid Tumor Models • Kymera's STAT3 degrader assessed in colorectal cancers (CT-26) known to be refractory to approved immunotherapies STAT3 degrader significantly reduced tumor growth when administered every two days Analysis of tumors showed synergistic modulation of immune cells (M2/M1 and T cells) within the tumor microenvironment to favor an anti-tumor response Tumor Volume (mm³) mean 3500 3000 2500 2000 1500 1000 500 Vehicle STAT3 Degrader 25 mg/kg, q2d 5 10 Days HH 1.5 20 % Population % Population Macrophages (M1/M2) 100 9 80 9 8 M1 T Cells CD8+ Vehicle STAT3 Degrader Vehicle STAT3 Degrader

View entire presentation